PT2419144T - Composição para a administração de material genético - Google Patents
Composição para a administração de material genéticoInfo
- Publication number
- PT2419144T PT2419144T PT10714058T PT10714058T PT2419144T PT 2419144 T PT2419144 T PT 2419144T PT 10714058 T PT10714058 T PT 10714058T PT 10714058 T PT10714058 T PT 10714058T PT 2419144 T PT2419144 T PT 2419144T
- Authority
- PT
- Portugal
- Prior art keywords
- delivery
- composition
- genetic material
- genetic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0906693A GB0906693D0 (en) | 2009-04-17 | 2009-04-17 | Composition and method |
GB0906692A GB0906692D0 (en) | 2009-04-17 | 2009-04-17 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2419144T true PT2419144T (pt) | 2019-09-16 |
Family
ID=42333482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT10714058T PT2419144T (pt) | 2009-04-17 | 2010-04-15 | Composição para a administração de material genético |
Country Status (8)
Country | Link |
---|---|
US (6) | US20130053426A1 (pt) |
EP (3) | EP4122498A1 (pt) |
JP (1) | JP5713325B2 (pt) |
CN (1) | CN102497887A (pt) |
DK (1) | DK2419144T3 (pt) |
ES (2) | ES2927225T3 (pt) |
PT (1) | PT2419144T (pt) |
WO (1) | WO2010119256A1 (pt) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
JP5713325B2 (ja) | 2009-04-17 | 2015-05-07 | アイシス イノヴェイション リミテッド | 遺伝物質の送達用の組成物 |
NZ600616A (en) | 2009-12-01 | 2014-11-28 | Shire Human Genetic Therapies | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
WO2011106376A2 (en) * | 2010-02-23 | 2011-09-01 | The General Hospital Corporation | Use of microvesicles in the treatment of medical conditions |
US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
WO2012091136A1 (ja) * | 2010-12-28 | 2012-07-05 | 学校法人東京医科大学 | 発現ベクター、それを用いたキャリアの製造方法およびその用途 |
WO2012162563A2 (en) * | 2011-05-24 | 2012-11-29 | The Regents Of The University Of California | Method for exosomal biomarker detection by electric field-induced release and measurement |
EP4043025A1 (en) | 2011-06-08 | 2022-08-17 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
GB201121070D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
GB201121069D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | Delivery system |
US10227593B2 (en) | 2011-12-13 | 2019-03-12 | Henry Ford Health System | Methods, systems, and compositions for cell-derived/vesicle-based microRNA delivery |
US9555060B2 (en) * | 2011-12-13 | 2017-01-31 | Henry Ford Health System | Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery |
CA2868506C (en) * | 2012-04-03 | 2023-10-24 | Reneuron Limited | Stem cell microparticles |
US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
WO2014054588A1 (ja) * | 2012-10-01 | 2014-04-10 | 国立大学法人京都大学 | ナノゲル/エキソソーム複合体とdds |
CN103865942A (zh) * | 2012-12-18 | 2014-06-18 | 常州碳宇纳米科技有限公司 | 一种可提高基因转染效率的纳米粒子和基于该粒子的基因转染试剂的制备 |
US10308959B2 (en) | 2013-01-18 | 2019-06-04 | Henry Ford Health System | Methods, systems, and compositions relating to MiRNA-146a |
ES2778098T3 (es) | 2013-03-13 | 2020-08-07 | Univ Miami | Método de aislamiento y purificación de microvesículas de sobrenadantes de cultivo celular y fluidos biológicos |
ES2708561T3 (es) | 2013-03-14 | 2019-04-10 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
PE20151773A1 (es) | 2013-03-14 | 2015-12-20 | Shire Human Genetic Therapies | COMPOSICIONES DE ARNm DE CFTR, METODOS Y USOS RELACIONADOS |
JP6137894B2 (ja) * | 2013-03-22 | 2017-05-31 | 国立大学法人京都大学 | リポソーム−エキソソームハイブリッドベシクル及びその調製法 |
PT2983721T (pt) * | 2013-04-12 | 2018-03-13 | Evox Therapeutics Ltd | Vesículas de entrega terapêutica |
US10538570B2 (en) * | 2013-09-30 | 2020-01-21 | Northwestern University | Targeted and modular exosome loading system |
MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
EP4276176A3 (en) | 2013-10-22 | 2024-01-10 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
CN104726410B (zh) * | 2013-12-23 | 2019-09-17 | 浙江大学 | 一种具有免疫抑制功能的外排体及其应用 |
EA037503B1 (ru) * | 2014-01-21 | 2021-04-05 | Анджариум Байосайенсиз Аг | Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства |
WO2015161184A1 (en) * | 2014-04-18 | 2015-10-22 | University Of Massachusetts | Exosomal loading using hydrophobically modified oligonucleotides |
KR20220158867A (ko) | 2014-04-25 | 2022-12-01 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
EP3173143A4 (en) | 2014-07-24 | 2018-06-27 | Toppan Printing Co., Ltd. | Lipid membrane structure, lipid-membrane-structure-immobilization carrier, and method for fusing cells |
WO2016044947A1 (en) * | 2014-09-26 | 2016-03-31 | Exerkine Corporation | Exosomes useful to treat lysosomal storage disease |
WO2016115632A1 (en) * | 2015-01-21 | 2016-07-28 | Exerkine Corporation | Method for treating mitochondrial disease |
KR20160130937A (ko) * | 2015-05-04 | 2016-11-15 | 한국과학기술원 | 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법 |
WO2016179417A2 (en) * | 2015-05-06 | 2016-11-10 | The University Of Utah Research Foundation | Exosome delivery of micrornas |
AU2016275046B2 (en) | 2015-06-10 | 2022-07-28 | Board Of Regents, The University Of Texas System | Use of exosomes for the treatment of disease |
WO2017042816A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Ablation of perforin positive dendritic cells in cancer treatment |
US9840542B2 (en) * | 2015-09-11 | 2017-12-12 | Nomadogen Biotechnologies Inc. | Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells |
US10624849B2 (en) * | 2015-09-28 | 2020-04-21 | Northwestern University | Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites |
CN108697740A (zh) | 2015-11-18 | 2018-10-23 | 佐治亚大学研究基金会 | 神经细胞细胞外囊泡 |
WO2017147720A1 (en) * | 2016-03-04 | 2017-09-08 | Exerkine Corporation | Method for treating a central nervous system disorder |
US20190112351A1 (en) * | 2016-04-04 | 2019-04-18 | National Institutes Of Biomedical Innovation, Health And Nutrition | Exosome-targeted dna vaccine |
GB2552473A (en) * | 2016-07-21 | 2018-01-31 | Evox Therapeutics Ltd | Surface decoration of extracellular vesicles |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
WO2018049284A1 (en) * | 2016-09-09 | 2018-03-15 | Cornell University | Delivery of nucleic acids, proteins and small molecules in vitreous vesicular bodies |
WO2018089901A2 (en) * | 2016-11-14 | 2018-05-17 | Joslin Diabetes Center | Exosome delivery system |
US20200069594A1 (en) * | 2016-12-09 | 2020-03-05 | Board Of Regents, The University Of Texas System | Hybrid exosomal-polymeric (hexpo) nano-platform for delivery of rnai therapeutics |
AU2018224326B2 (en) | 2017-02-27 | 2024-01-04 | Translate Bio, Inc. | Novel codon-optimized CFTR mRNA |
EP3610004A4 (en) * | 2017-04-12 | 2021-01-27 | Shenzhen International Institute for Biomedical Research | PUM PROTEIN 1 AS A TARGET FOR VIRUS INHIBITION |
US11173190B2 (en) | 2017-05-16 | 2021-11-16 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR |
JP7420708B2 (ja) * | 2017-08-04 | 2024-01-23 | オハイオ・ステイト・イノベーション・ファウンデーション | ナノエレクトロポレーション及び他の非エンドサイトーシスの細胞トランスフェクションから、治療用の細胞外小胞を生産する方法 |
CA3073162C (en) * | 2017-08-17 | 2023-07-04 | Ilias Biologics Inc. | Exosomes for target specific delivery and methods for preparing and delivering the same |
AU2018333072B2 (en) | 2017-09-18 | 2022-09-29 | Cz Biohub Sf, Llc | Methods for treating triple-negative breast cancer |
WO2019067587A1 (en) | 2017-09-26 | 2019-04-04 | University Of Florida Research Foundation, Incorporated | USE OF METFORMIN AND ANALOGUES THEREOF TO REDUCE RAN PROTEIN RATES DURING TREATMENT OF NEUROLOGICAL DISORDERS |
GB2568255A (en) | 2017-11-08 | 2019-05-15 | Evox Therapeutics Ltd | Exosomes comprising RNA therapeutics |
WO2019099927A1 (en) * | 2017-11-16 | 2019-05-23 | Board Of Regents, The University Of Texas System | Methods for production of msc-derived exosomes |
JP2021503300A (ja) * | 2017-11-17 | 2021-02-12 | コディアック バイオサイエンシーズ, インコーポレイテッド | 操作エクソソームの組成物及び内腔エクソソームペイロードの搭載方法 |
US20190153409A1 (en) * | 2017-11-17 | 2019-05-23 | Aviv MedTech Ltd. | Compositions comprising particles and methods for treating cancer |
EA202091134A1 (ru) * | 2017-12-28 | 2020-11-20 | Кодиак Байосайенсес, Инк. | Экзосомы для иммуноонкологической и противовоспалительной терапии |
CN112218621A (zh) * | 2018-04-10 | 2021-01-12 | 西北大学 | 包含基于靶向亲和域的膜蛋白的胞外囊泡 |
US20210315819A1 (en) * | 2018-06-28 | 2021-10-14 | Astrazeneca Ab | Exosome extracellular vesicles and methods of use |
WO2020030561A1 (en) | 2018-08-10 | 2020-02-13 | Unicyte Ev Ag | Extracellular vesicles loaded with an exogenous molecule |
AU2019325702A1 (en) | 2018-08-24 | 2021-02-25 | Translate Bio, Inc. | Methods for purification of messenger RNA |
EP3620519A1 (en) * | 2018-09-04 | 2020-03-11 | F. Hoffmann-La Roche AG | Use of isolated milk extracellular vesicles for delivering oligonucleotides orally |
WO2020154210A1 (en) * | 2019-01-22 | 2020-07-30 | Research Institute At Nationwide Children's Hospital | Methods for detecting and treating hepatic cancers |
US20210379192A1 (en) * | 2019-01-25 | 2021-12-09 | Mantra Bio, Inc. | Skeletal muscle targeting moieties and uses thereof |
CN109701038B (zh) * | 2019-02-22 | 2021-02-23 | 上海大学 | 一种脑部靶向外泌体、其制备方法及应用 |
GB201906482D0 (en) | 2019-05-08 | 2019-06-19 | Evox Therapeutics Ltd | Exosome comprising stabilized RNA therapeutics |
JP2022549654A (ja) * | 2019-09-23 | 2022-11-28 | ユニバーシティー オブ フロリダ リサーチ ファンデーション, インク. | Ranタンパク質疾患のためのワクチン治療 |
CN112972702A (zh) * | 2019-12-17 | 2021-06-18 | 南京大学 | 用于治疗耐药菌感染的外泌体制剂 |
CA3164176A1 (en) * | 2020-01-13 | 2021-07-22 | Carmine Therapeutics Pte. Ltd. | Nucleic acid loaded red blood cell extracellular vesicles |
EP4132479A1 (en) | 2020-04-07 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Cannabidiol-containing compositions and uses thereof |
AU2021255132A1 (en) | 2020-04-13 | 2022-12-08 | Exoprother Medical Ltd. | Cell-derived vesicles comprising wild-type P53 protein for antiviral therapy |
US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
US20220072049A1 (en) | 2020-08-21 | 2022-03-10 | University Of Miami | Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells |
CN117813319A (zh) * | 2021-03-15 | 2024-04-02 | 俄亥俄州立创新基金会 | 基于细胞外囊泡的纳米载体 |
IT202100007304A1 (it) * | 2021-03-25 | 2022-09-25 | Exo Lab Italia | Metodo di applicazione di impulsi elettrici allo scopo di caricare molecole di varia natura in nanovescicole di origine vegetale |
WO2023102550A2 (en) | 2021-12-03 | 2023-06-08 | The Broad Institute, Inc. | Compositions and methods for efficient in vivo delivery |
WO2023183860A1 (en) * | 2022-03-23 | 2023-09-28 | University Of Delaware | Engineered extracellular vesicles for targeted drug delivery to muscle |
WO2023205158A1 (en) | 2022-04-19 | 2023-10-26 | University Of Miami | Compositions comprising microvesicles for use in the prevention and treatment of graft versus host disease |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4203413C2 (de) | 1992-02-06 | 1993-11-25 | Fraunhofer Ges Forschung | Mehrfachabtastungsverfahren |
US5166646A (en) | 1992-02-07 | 1992-11-24 | Motorola, Inc. | Integrated tunable resonators for use in oscillators and filters |
DE69635895D1 (de) | 1995-08-03 | 2006-05-04 | Rijksuniversiteit Te Leiden Le | Antigen presentierende bläschen, die von zellen ableiten |
US6669835B1 (en) | 1997-02-18 | 2003-12-30 | Atofina Chemicals, Inc. | Aqueous dispersions of polymerizable reactants and a water incompatible catalyst sorbed on an inorganic particulate carrier |
FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
US6645490B2 (en) * | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
FR2785543B1 (fr) | 1998-11-05 | 2003-02-28 | Inst Nat Sante Rech Med | Exosomes modifies et utilisations |
US6627421B1 (en) | 1999-04-13 | 2003-09-30 | Imarx Therapeutics, Inc. | Methods and systems for applying multi-mode energy to biological samples |
GB9927320D0 (en) * | 1999-11-18 | 2000-01-12 | Chiron Spa | Exosome separation |
US20040241176A1 (en) | 2000-04-27 | 2004-12-02 | Ap Cells. Inc. | Method of producing membrane vesicles |
FR2812813B1 (fr) * | 2000-08-09 | 2004-11-26 | Neovacs | Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires |
CA2454756C (en) | 2001-08-17 | 2014-02-18 | Anosys, Inc. | Methods and compounds for the targeting of protein to exosomes |
KR100519384B1 (ko) | 2002-08-13 | 2005-10-06 | (주)누백스 | 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도 |
JP4939926B2 (ja) * | 2003-02-14 | 2012-05-30 | アノシス・インコーポレーテッド | 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド |
JP2006518219A (ja) | 2003-02-18 | 2006-08-10 | マックスサイト インコーポレーティッド | 電気穿孔法による細胞への抗原の負荷方法 |
US20050153304A1 (en) | 2003-04-10 | 2005-07-14 | Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Multivariate profiling of complex biological regulatory pathways |
EP1537858A1 (en) * | 2003-12-04 | 2005-06-08 | Vectron Therapeutics AG | Drug delivery vehicles and uses thereof |
CN1322115C (zh) * | 2005-07-06 | 2007-06-20 | 清华大学 | 载有外源配体分子的胞外体及其制备方法与应用 |
US9085778B2 (en) * | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
JP2010508592A (ja) * | 2006-10-27 | 2010-03-18 | ジャンプタップ,インコーポレイテッド | アルゴリズム上の再検討及び編集上の再検討の組み合わせによるモバイルコンテンツの検索結果 |
CN101641010A (zh) | 2007-01-26 | 2010-02-03 | 路易斯维尔大学研究基金会公司 | 用作疫苗的外来体组分的修饰 |
US20110177054A1 (en) | 2008-06-06 | 2011-07-21 | Derrick Gibbings | Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna |
JP5713325B2 (ja) | 2009-04-17 | 2015-05-07 | アイシス イノヴェイション リミテッド | 遺伝物質の送達用の組成物 |
US20120135542A1 (en) | 2009-06-05 | 2012-05-31 | Mayo Foundation For Medical Education And Research | Methods and materials for diagnosing light chain amyloidosis |
CN107412755A (zh) | 2009-07-02 | 2017-12-01 | Ith免疫治疗控股公司 | 基于外泌体的癌症治疗 |
EP2270969B8 (en) | 2009-07-02 | 2012-04-11 | Converteam Technology Ltd | Control methods for parallel-connected power converters |
WO2011011733A2 (en) | 2009-07-24 | 2011-01-27 | The Regents Of The University Of Michigan | Factor replacement therapy |
GB201121070D0 (en) | 2011-12-07 | 2012-01-18 | Isis Innovation | composition for delivery of biotherapeutics |
BR112015016018A2 (pt) | 2013-01-03 | 2017-07-11 | Unilever Nv | composição para cuidado dos cabelos |
-
2010
- 2010-04-15 JP JP2012505223A patent/JP5713325B2/ja active Active
- 2010-04-15 EP EP22178389.7A patent/EP4122498A1/en active Pending
- 2010-04-15 ES ES19178842T patent/ES2927225T3/es active Active
- 2010-04-15 EP EP10714058.4A patent/EP2419144B1/en active Active
- 2010-04-15 US US13/264,485 patent/US20130053426A1/en not_active Abandoned
- 2010-04-15 CN CN2010800268640A patent/CN102497887A/zh active Pending
- 2010-04-15 DK DK10714058.4T patent/DK2419144T3/da active
- 2010-04-15 EP EP19178842.1A patent/EP3569254B1/en active Active
- 2010-04-15 PT PT10714058T patent/PT2419144T/pt unknown
- 2010-04-15 ES ES10714058T patent/ES2749393T3/es active Active
- 2010-04-15 WO PCT/GB2010/000762 patent/WO2010119256A1/en active Application Filing
-
2015
- 2015-09-08 US US14/847,853 patent/US10233445B2/en active Active
-
2016
- 2016-11-30 US US15/364,794 patent/US10329561B2/en active Active
-
2019
- 2019-01-31 US US16/264,257 patent/US10704047B2/en active Active
-
2020
- 2020-04-24 US US16/857,803 patent/US11230715B2/en active Active
-
2021
- 2021-12-13 US US17/548,995 patent/US20220098589A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20130053426A1 (en) | 2013-02-28 |
US20200308587A1 (en) | 2020-10-01 |
EP2419144B1 (en) | 2019-08-07 |
US10233445B2 (en) | 2019-03-19 |
US11230715B2 (en) | 2022-01-25 |
WO2010119256A1 (en) | 2010-10-21 |
EP4122498A1 (en) | 2023-01-25 |
DK2419144T3 (da) | 2019-10-21 |
CN102497887A (zh) | 2012-06-13 |
ES2927225T3 (es) | 2022-11-03 |
US10704047B2 (en) | 2020-07-07 |
EP3569254B1 (en) | 2022-07-20 |
EP2419144A1 (en) | 2012-02-22 |
JP2012524052A (ja) | 2012-10-11 |
US20190153445A1 (en) | 2019-05-23 |
US20170182182A1 (en) | 2017-06-29 |
ES2749393T3 (es) | 2020-03-20 |
US10329561B2 (en) | 2019-06-25 |
JP5713325B2 (ja) | 2015-05-07 |
US20160067355A1 (en) | 2016-03-10 |
US20220098589A1 (en) | 2022-03-31 |
EP3569254A1 (en) | 2019-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2419144T (pt) | Composição para a administração de material genético | |
HK1252488A1 (zh) | 用於核酸遞送的組合物 | |
HK1210223A1 (en) | Compositions for inhibiting gene expression and uses thereof | |
EP2504448A4 (en) | METHOD AND COMPOSITION FOR DETECTING GENETIC MATERIAL | |
IL215608A0 (en) | Drug delivery composition | |
AP3284A (en) | Compositions for targeted delivery of SIRNA | |
HK1170679A1 (en) | Compositions and methods for drug delivery | |
EP2512449A4 (en) | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF NUCLEIC ACIDS | |
EP2493474A4 (en) | METHOD AND COMPOSITIONS FOR DELAYED ACTIVE INGREDIENT EXTRACTION | |
GB0913683D0 (en) | Fire-resistant composition material | |
HUE042850T2 (hu) | Készítmények hatóanyag szállításra | |
HK1160034A1 (zh) | 用於吸入的藥用組合物 | |
EP2776056A4 (en) | NEW COMPOSITION FOR GENETIC RELIEF | |
ZA201100432B (en) | Granulation of molten material | |
ZA201106651B (en) | Composition comprising delivery particles | |
ZA201003844B (en) | Delivery of functional compounds | |
GB0912177D0 (en) | Contained transfer of material | |
EP2600900A4 (en) | SUPRAMOLECULAR MULTIPLEX AGGREGATES FOR THE NONVIRAL OUTPUT OF GENETIC MATERIALS | |
EP2440192A4 (en) | COMPOSITIONS AND METHODS FOR ADMINISTERING MATERIALS | |
EP2415482A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF METASTASIS | |
GB0908685D0 (en) | Composition for intraocular delivery | |
ZA201209683B (en) | Pharmaceutical compositions for sublingual delivery of opioids | |
EP2437735A4 (en) | COMPOSITIONS AND METHODS FOR ADMINISTERING SUBSTANCES | |
PL387126A1 (pl) | Tworzywo ogniotrwałe | |
HU0900010D0 (en) | Improved pharmaceutical composition |